Monopar Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Monopar Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+29%Cash, after subtracting all debt, equals 29% of its market value (net cash).
Higher than 68% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Monopar Therapeutics Inc. made a loss over the last year. Monopar Therapeutics Inc. owes $0.03 for every $1 it owns. Monopar Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMonopar Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.72The share price is 3.72 times Monopar Therapeutics Inc.'s book value per share, higher than 63% of Healthcare companies in United States.
Market cap
$487 MThe total market value of all of Monopar Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$131 MWhat Monopar Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$19.50Net worth divided by the number of shares. The share price of $72.58 is 3.7 times this, which is the P/B above.
Return on equity (ROE)
-19.5%Monopar Therapeutics Inc. lost 19.5% of its shareholders' money over the last year, higher than 66% of Healthcare companies in United States.
Owes vs Owns
0.03×Monopar Therapeutics Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Dividend yield
NoneMonopar Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossMonopar Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net cashMonopar Therapeutics Inc. held $140 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Monopar Therapeutics Inc.: $487 M ÷ $131 M (30 Jun 2026) = 3.7.
What is Monopar Therapeutics Inc.'s return on equity?
Monopar Therapeutics Inc. lost 19.5% of its shareholders' money over the last year, higher than 66% of Healthcare companies in United States.
How much does Monopar Therapeutics Inc. owe compared with what it owns?
Monopar Therapeutics Inc. owes $0.03 for every $1 it owns (low), lower than almost all Healthcare companies in United States.
Does Monopar Therapeutics Inc. pay a dividend?
No. Monopar Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.